Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is a multi-centre Phase I trial of pre-operative, margin intensive, stereotactic body radiation therapy (SBRT) for previously untreated borderline resectable pancreatic cancer.

Study Design

Phase I rolling six design dose escalation study testing the use of Stereotactic Body Radiation Therapy (SBRT) delivered in the pre-operative setting for pancreatic cancers.

Primary Objectives

  • To establish the maximum tolerated dose (MTD) of margin-intensive SBRT delivered pre-operatively in the management of pancreatic cancer

Secondary Objectives:

  • To examine key clinical outcomes for patients treated with this regimen, namely:
    • Surgical resection rates
    • Resection margin status
    • Response rates
  • Late SBRT toxicity (>1 month to 6 months post-surgery or to 6 months post SBRT for patients not proceeding to surgery)
  • Efficacy and long term safety of SBRT delivered pre-operatively in the management of pancreatic cancer

Key Dates

First site open to recruitment: 17 April 2015
Planned accrual completion: 17 April 2017
Trial duration: 39 months

Our team

  • Sarah Pearson

    OCTO Trial Management Director